CATABASIS PHARMACEUTICALS IN's ticker is and the CUSIP is 14875P206. A total of 26 filers reported holding CATABASIS PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $34,000 | +21.4% | 11,801 | -9.5% | 0.00% | – |
| Q4 2020 | $28,000 | -50.9% | 13,044 | +42.3% | 0.00% | – |
| Q3 2020 | $57,000 | +7.5% | 9,167 | +10.4% | 0.00% | – |
| Q2 2020 | $53,000 | +71.0% | 8,305 | +55.7% | 0.00% | – |
| Q4 2019 | $31,000 | -85.4% | 5,333 | -80.2% | 0.00% | – |
| Q1 2019 | $213,000 | -45.5% | 26,906 | -70.0% | 0.00% | – |
| Q4 2018 | $391,000 | – | 89,682 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 4,092,166 | $8,634,000 | 3.55% |
| COMMODORE CAPITAL LP | 1,617,000 | $3,412,000 | 1.19% |
| ACUTA CAPITAL PARTNERS, LLC | 1,173,674 | $2,476,000 | 0.99% |
| VR Adviser, LLC | 3,234,000 | $6,824,000 | 0.83% |
| Logos Global Management LP | 3,190,000 | $6,731,000 | 0.57% |
| Cormorant Asset Management, LP | 3,550,000 | $7,490,000 | 0.25% |
| Soleus Capital Management, L.P. | 775,000 | $1,635,000 | 0.25% |
| Perceptive Advisors | 15,374,370 | $32,438,000 | 0.21% |
| RA Capital Management | 5,947,861 | $12,550,000 | 0.20% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 188,777 | $398,000 | 0.18% |